HighVolumeHDF® as easy as HD.
Helixone® has been specially designed to meet the demands of both low-flux and high-flux therapies:
No chemical residuals. Low rinsing volumes. Lower costs.
| FX low-flux dialysers | FX 5 | FX 8 | FX 10 | |
|---|---|---|---|---|
| Ultrafiltration coefficient (ml/h x mmHg) | 8 | 12 | 14 | |
| Clearance: QB: (200ml/min) | ||||
| Urea | 180 | 191 | 193 | |
| Creatinine | 165 | 178 | 181 | |
| Phosphate | 141 | 160 | 170 | |
| Vitamin B12 | 88 | 107 | 121 | |
| Clearance: QB: (300ml/min) | ||||
| Urea | 228 | 254 | 261 | |
| Creatinine | 200 | 225 | 231 | |
| Phosphate | 164 | 194 | 210 | |
| Vitamin B12 | 94 | 120 | 138 | |
| Clearance: QB: (400ml/min) | ||||
| Urea | 293 | 303 | ||
| Creatinine | 252 | 260 | ||
| Phosphate | 213 | 233 | ||
| Vitamin B12 | 126 | 146 | ||
| The in vitro performance data were obtained with QD = 500ml/min: QF = 0ml/min; T=37°C (ISO8637) The ultrafiltration coefficients were maintained using human blood, Hct = 32%, protein content 6% | ||||
| Effective surface area (m²) | 1.0 | 1.4 | 1.8 | |
| Blood filling volume (ml) | 54 | 74 | 95 | |
| Membrane material | Helixone® | |||
| Housing material | Polypropylene | |||
| Potting compound | Polyurethane | |||
| Sterilisation method | INLINE steam | |||
| Application | HD | |||
| FX high-flux dialysers | FX 40 | FX 50 | FX 60 | FX 80 | FX 100 |
|---|---|---|---|---|---|
| Ultrafiltration coefficient (ml/h x mmHg) | 20 | 33 | 46 | 59 | 73 |
| Clearance: QB: (200ml/min) | |||||
| Urea | 170 | 189 | 193 | 197 | |
| Creatinine | 144 | 170 | 182 | 189 | |
| Phosphate | 138 | 165 | 177 | 185 | |
| Vitamin B12 | 84 | 115 | 135 | 148 | |
| Inulin | 54 | 76 | 95 | 112 | |
| Clearance: QB: (300ml/min) | |||||
| Urea | 250 | 261 | 276 | 278 | |
| Creatinine | 210 | 230 | 250 | 261 | |
| Phosphate | 201 | 220 | 239 | 248 | |
| Vitamin B12 | 130 | 155 | 175 | 192 | |
| Inulin | 81 | 104 | 125 | 142 | |
| Clearance: QB: (400ml/min) | |||||
| Urea | 303 | 362 | 331 | ||
| Creatinine | 262 | 287 | 304 | ||
| Phosphate | 248 | 272 | 284 | ||
| Vitamin B12 | 167 | 190 | 213 | ||
| Inulin | 109 | 133 | 152 | ||
| The in vitro performance data were obtained with QD = 500ml/min: QF = 0ml/min; T=37°C (ISO8637) The ultrafiltration coefficients were maintained using human blood, Hct = 32%, protein content 6% | |||||
| Effective surface area (m²) | 0.6 | 1.0 | 1.4 | 1.8 | 2.2 |
| Blood filling volume (ml) | 32 | 53 | 74 | 95 | 116 |
| Membrane material | Helixone® | ||||
| Housing material | Polypropylene | ||||
| Potting compound | Polyurethane | ||||
| Sterilisation method | INLINE steam | ||||
| Application | HD/HDF/HF | ||||
| FX hemodiafilters | FX 600 | FX 800 | FX 1000 |
|---|---|---|---|
| Ultrafiltration coefficient (ml/h x mmHg) | 52 | 63 | 75 |
| Clearance: QB: (200ml/min)QF: (0ml/min) | |||
| Urea | 196 | 198 | |
| Creatinine | 184 | 190 | |
| Phosphate | 180 | 184 | |
| Vitamin B12 | 141 | 149 | |
| Inulin | 101 | 110 | |
| Clearance: QB: (300ml/min) QF: (75ml/min) | |||
| Urea | 284 | 289 | 290 |
| Creatinine | 262 | 271 | 280 |
| Phosphate | 254 | 262 | 269 |
| Vitamin B12 | 199 | 209 | 211 |
| Inulin | 150 | 161 | 164 |
| Clearance: QB: (400ml/min) QF: (100ml/min) | |||
| Urea | 351 | 361 | 364 |
| Creatinine | 313 | 328 | 343 |
| Phosphate | 301 | 313 | 325 |
| Vitamin B12 | 229 | 241 | 244 |
| Inulin | 172 | 185 | 188 |
| The in vitro performance data were obtained with QD = 500ml/min: T=37°C (ISO8637) The ultrafiltration coefficients were maintained using human blood, Hct = 32%, protein content 6% | |||
| Effective surface area (m²) | 1.5 | 1.8 | 2.2 |
| Wall thickness / inner diameter (µm) | 35/210 | ||
| Blood filling volume (ml) | 97 | 118 | 138 |
| Membrane material | Helixone® | ||
| Housing material | Polypropylene | ||
| Potting compound | Polyurethane | ||
| Sterilisation method | INLINE steam | ||
| Application | HD/HDF | ||
Additional information relating to multiBic or Calrecia can be found in the critical care section of our product information page.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to Fresenius Medical Care on 01623 445215 or VigilanceUK@freseniusmedicalcare.com
UK-All-000020. Date of Preparation: June 2026.
1 Bowry, S.K.: Nano-controlled membrane spinning technology: Regulation of pore size, distribution and morphology of a new polysulfone dialysis membrane. In Hemodialysis Technology (eds: Ronco, C., La Greca, G.) Contributions to Nephrology, Vol. 137: 85-94 (2002)
2 Ronco, C., Nissenson, A.R.: Does nanotechnology apply to dialysis? Blood Purification 19: 347-352 (2001)